Prostate Cancer Clinical Trial
— FOCUS-BOOSTOfficial title:
Interstitial Brachytherapy of the Prostate With Iodine 125 Implant With Target Dose Supplementation in the Tumor Volume Guided by the TRINITY® PERINE 3D Ultrasound System
NCT number | NCT05322356 |
Other study ID # | 2021-A01178-33 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | April 4, 2023 |
Est. completion date | June 2025 |
The objective of the FOCUS-Boost project is to implant for the first time with a 3D ultrasound image fusion registration system (3D echo) implant of iodine 125 with precision in a target volume determined by positive biopsies.
Status | Recruiting |
Enrollment | 15 |
Est. completion date | June 2025 |
Est. primary completion date | May 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - At least 18 years - Patient to be treated with brachytherapy - Patient with low or favorable intermediate risk prostate adenocarcinoma ISUP 1 and 2, G6 (3+3) or G7 (3+4) - Life expectancy of more than 10 years - PSA (prostate-specific antigen) < 15 ng/ml - cT1c or cT2a or cT2b - Prostate volume = 60 cc - ECOG Performance status 0-2 - Patient is affiliated to a health insurance system - Patient who has signed consent form Exclusion Criteria: - Patient with urinary function disorders IPSS> 14 - Prostate volume > 60cc. - Gleason 7(4+3) or Gleason score =8 - PSA = 15 ng/ml - Patient with metastases - Hormone therapy with antiandrogen or LHRH analogue - History of abdominopelvic irradiation - Inflammatory digestive disease (haemorrhagic rectocolitis, Crohn's disease) - Interventional study in progress that may interfere with the present study - Protected persons (patient concerned by articles L1121-5, L1121-6, L1121-8 of the French public health code) |
Country | Name | City | State |
---|---|---|---|
France | Isabelle Boudry | Grenoble |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Grenoble | Clinical Investigation Centre for Innovative Technology Network, Koelis |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Implant for the first time, in a clinical situation, iodine 125 implants in a planned target volume, using a 3D echo-mapping fusion guidance system of positive biopsies. | To evaluate the number of successful/failed iodine 125 implants (BOOST implants) implanted in the CTV-boost (Clinical Target Volume) defined from the mapping of positive biopsies. The maximum number of BOOST implant implanted will be 4 implants, depending on the size of the target: 10 mm< target = 15 mm = 2 implants; 15 mm < target = 20mm = 3 implants; 20 mm < target = 30 mm = 4 implants; Success is defined as "the centre of the implant is in the target volume". Failure is defined as "the centre of the implant is outside the target volume". The primary endpoint is evaluated on the ultrasound acquisition performed with the Trinity® Perine probe, at the end of the BOOST implant insertion procedure |
24 hours | |
Secondary | Assess toxicity (pre brachytherapy visit, M1, M3, M6, M12), with questionnaires | Assessment of toxicity by questionnaires (IPSS score + urinary symptom quality of life). IPSS:: International Prostate Score Symptom (0 to 35: Score 20-35: severely symptomatic. Score 8-19: moderately symptomatic) |
12 months | |
Secondary | Assess toxicity (pre brachytherapy visit, M1, M12) with flowmetry | Assessment of toxicity by urinary flowmetry | 12 months | |
Secondary | Assess toxicity (pre brachytherapy visit, M1, M3, M6, M12) with CTCAE score | Assessment of toxicity by classification of toxicities according to CTCAE score (Common Terminology Criteria for Adverse Events: Grade 1 Mild / Grade 2 Moderate / Grade 3 Severe or medically significant but not immediately life-threatening / Grade 4 Life-threatening consequences / Grade 5 Death related to A | 12 months | |
Secondary | To assess the efficacy of the treatment at M6 and M12. | PSA (Prostate Specific Antigen) test | 12 months | |
Secondary | To check the absence of overdose in the prostate at D0 and M1. | V150% < 60% of prostate volume on CT dosimetry at D0 and 1 month | 1 month | |
Secondary | To check the absence of overdose in organs at risk (bladder, urethra, rectum) at D0 and M1. | Absence of overdose in organs at risk on scanner dosimetry | 1 month | |
Secondary | Dose to CTV-dosi at 150% | V150% > 95% for CTV-dosi (on Variseed dosimetry) at J0 | 1 month | |
Secondary | Assess quality of life (inclusion, M1, M3, M6, M12). | QLQ-C30 (Quality of Life Questionnaire) score | 12 months | |
Secondary | Assess sexual health (inclusion, M1, M3, M6, M12). | IIEF5 questionnaire score (Erectile dysfunction severe (score 5-10), moderate (11-15), mild (16-20), normal erectile function (21-25) and uninterpretable (1-4)). | 12 months | |
Secondary | Measure the duration of the complete procedure, the additional act (BOOST) and the final ultrasound acquisition performed at the end of the procedure (when performed). | Duration of the entire procedure, the additional procedure (BOOST), and the final ultrasound acquisition at the end of the procedure (when performed) | 24 hours | |
Secondary | (For the last 5 patients): Estimate the quality of the registration after insertion of the implants. | (For the last 5 patients): Final ultrasound acquisition performed at the end of the procedure with the Trinity® Perine system | 24 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |